Independent Advisor Alliance Trims Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Independent Advisor Alliance reduced its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 85.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,812 shares of the medical equipment provider’s stock after selling 16,592 shares during the quarter. Independent Advisor Alliance’s holdings in Zimmer Biomet were worth $253,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBH. M&T Bank Corp boosted its stake in shares of Zimmer Biomet by 15,705.6% during the 4th quarter. M&T Bank Corp now owns 3,571,595 shares of the medical equipment provider’s stock valued at $321,158,000 after buying an additional 3,548,998 shares during the last quarter. Dodge & Cox boosted its stake in shares of Zimmer Biomet by 5.1% during the 3rd quarter. Dodge & Cox now owns 23,216,173 shares of the medical equipment provider’s stock valued at $2,286,793,000 after buying an additional 1,118,710 shares during the last quarter. AQR Capital Management LLC boosted its stake in shares of Zimmer Biomet by 276.6% during the 2nd quarter. AQR Capital Management LLC now owns 1,300,593 shares of the medical equipment provider’s stock valued at $118,627,000 after buying an additional 955,284 shares during the last quarter. Capital International Investors boosted its stake in shares of Zimmer Biomet by 11.5% during the 3rd quarter. Capital International Investors now owns 7,550,754 shares of the medical equipment provider’s stock valued at $743,749,000 after buying an additional 778,467 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC boosted its stake in shares of Zimmer Biomet by 3,633.7% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 464,250 shares of the medical equipment provider’s stock valued at $45,729,000 after buying an additional 451,816 shares during the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Performance

Shares of ZBH opened at $85.09 on Tuesday. The business’s fifty day moving average price is $89.43 and its 200 day moving average price is $91.32. Zimmer Biomet Holdings, Inc. has a 12-month low of $79.12 and a 12-month high of $108.29. The stock has a market capitalization of $16.46 billion, a PE ratio of 22.10, a price-to-earnings-growth ratio of 1.94 and a beta of 0.48. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.73 and a quick ratio of 0.95.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.23. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The firm had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. During the same period last year, the business posted $1.81 earnings per share. The firm’s revenue for the quarter was up 9.3% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.47 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st were paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date was Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio (DPR) is presently 24.94%.

Analyst Upgrades and Downgrades

ZBH has been the subject of several research analyst reports. Citigroup reduced their target price on Zimmer Biomet from $98.00 to $95.00 and set a “neutral” rating for the company in a research note on Wednesday, April 29th. Wall Street Zen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. Wells Fargo & Company reduced their price objective on Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 29th. Truist Financial restated a “hold” rating and set a $92.00 price objective (down from $98.00) on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Finally, Canaccord Genuity Group set a $83.00 price objective on Zimmer Biomet in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and a consensus price target of $102.80.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total value of $250,849.00. Following the sale, the senior vice president directly owned 10,224 shares in the company, valued at approximately $967,803.84. This trade represents a 20.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 1.28% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.